Stay updated on Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check33 days agoNo Change Detected
- Check41 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference0.8%
- Check48 days agoChange DetectedThe study of trastuzumab deruxtecan for HER2-positive breast cancer has posted results indicating successful dose escalation and efficacy, with a focus on the maximum tolerated dose in combination with nivolumab, while previous statuses and details have been removed.SummaryDifference74%
- Check62 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check69 days agoChange DetectedThe website has added a new type of intervention with a verified status from August 2021, while the previous version has removed the type of intervention in the earlier revision.SummaryDifference0.6%
- Check98 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial page.